274 related articles for article (PubMed ID: 10604706)
1. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage.
Shekarriz B; Upadhyay J; Wood DP; Hinman J; Raasch J; Cummings GD; Grignon D; Littrup PJ
Urology; 1999 Dec; 54(6):1044-8. PubMed ID: 10604706
[TBL] [Abstract][Full Text] [Related]
2. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
[TBL] [Abstract][Full Text] [Related]
3. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
Scattoni V; Roscigno M; Raber M; Montorsi F; Da Pozzo L; Guazzoni G; Freschi M; Rigatti P
Eur Urol; 2003 Oct; 44(4):407-14. PubMed ID: 14499673
[TBL] [Abstract][Full Text] [Related]
4. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
5. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
6. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy.
Saleem MD; Sanders H; Abu El Naser M; El-Galley R
Urology; 1998 Feb; 51(2):283-6. PubMed ID: 9495712
[TBL] [Abstract][Full Text] [Related]
7. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
[TBL] [Abstract][Full Text] [Related]
8. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of the anatomo-pathological staging of radical prostatectomy specimens with the amount of cancer in the preoperative sextant biopsy].
Ojea Calvo A; Núñez López A; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; Gómez-González MC; González Piñeiro A; Otero García M; Nogueira March JL
Actas Urol Esp; 2003 Jun; 27(6):428-37. PubMed ID: 12918149
[TBL] [Abstract][Full Text] [Related]
10. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
11. Ability of sextant biopsies to predict radical prostatectomy stage.
Wills ML; Sauvageot J; Partin AW; Gurganus R; Epstein JI
Urology; 1998 May; 51(5):759-64. PubMed ID: 9610589
[TBL] [Abstract][Full Text] [Related]
12. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
14. [Role of prostate fossa ultrasonography in the diagnosis of local recurrence after radical prostatectomy in case of PSA failure].
Roscigno M; Scattoni V; Raber M; Consonni P; Montorsi F; Pasta A; Bertini R; Colombo R; Da Pozzo L; Freschi M; Rigatti P
Arch Ital Urol Androl; 2002 Dec; 74(4):304-8. PubMed ID: 12508759
[TBL] [Abstract][Full Text] [Related]
15. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
16. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
17. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer.
Bianco FJ; Wood DP; Cher ML; Powell IJ; Souza JW; Pontes JE
Clin Prostate Cancer; 2003 Mar; 1(4):242-7. PubMed ID: 15040883
[TBL] [Abstract][Full Text] [Related]
18. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW
Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653
[TBL] [Abstract][Full Text] [Related]
19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
20. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.
Gretzer MB; Epstein JI; Pound CR; Walsh PC; Partin AW
Urology; 2002 Dec; 60(6):1034-9. PubMed ID: 12475665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
